SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Vivos Reports 18% Lower Q3 Operating Loss, Regains Nasdaq Compliance

Vivos Therapeutics said its Q3 operating loss improved 18% year over year, with general and administrative and sales and marketing expenses down $1.6 million. The company regained compliance with Nasdaq’s stockholders’ equity requirement after its October SOD Sciences transaction.

VVOS

Vivos reported Q3 operating loss improved 18% year over year, with G&A and sales and marketing expenses down $1.6M. It regained compliance with Nasdaq’s stockholders’ equity requirement after its October SOD Sciences transaction.Material DetailsContext by AI AnalystThis is a quarterly results updat…

Related stories